442 material Form 8-K filings that 386 companies we cover made with the SEC in March 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
NCR Atleos reported fourth quarter 2024 revenue of $1.11 billion, up 1%, and GAAP net income attributable to Atleos of $46 million, compared with a loss of $165 million a year earlier. For full year 2024, revenue was $4.3 billion, up 3%, and GAAP diluted EPS was $1.23, compared with a loss of $1.90 in 2023. The company also issued 2025 guidance calling for constant-currency total revenue growth of 1% to 3%, Adjusted EBITDA growth of 7% to 10%, and non-GAAP diluted EPS growth of 21% to 27%.
Q4 2024 revenue $1.11 billion, up 1%; Q4 GAAP diluted EPS $0.61 versus a loss of $2.34 a year earlier
Full year 2024 operating cash flow $344 million; adjusted free cash flow-unrestricted $242 million
2025 guidance: total revenue growth 1% to 3% constant currency, with an estimated FX impact of -2%; adjusted free cash flow-unrestricted of $260 million to $300 million
Conference call scheduled for March 4, 2025 at 8:30 a.m. Eastern Time
Dave Inc. reported fourth quarter 2024 revenue of $100.9 million, up 38% from a year earlier, and net income of $16.8 million, compared with $0.2 million in the prior-year quarter. The company also issued 2025 guidance of $415 million to $435 million in GAAP operating revenue and $110 million to $120 million in Adjusted EBITDA, a non-GAAP measure.
Q4 2024 GAAP operating revenues, net: $100.9 million, up 38% year over year
Q4 2024 GAAP net income: $16.8 million, versus $0.2 million in Q4 2023; full-year 2024 net income was $57.9 million
Q4 2024 Adjusted EBITDA: $33.4 million, which the company says significantly exceeded the high end of its guidance
2025 guidance: revenue of $415 million to $435 million and Adjusted EBITDA of $110 million to $120 million
Okta reported fourth-quarter and full fiscal 2025 results for the period ended January 31, 2025, with revenue up 13% and a GAAP net profit in the quarter after a loss a year earlier. The company guided fiscal 2026 total revenue to $2.850 billion to $2.860 billion, or 9% to 10% growth, which is slower than the 15% full-year growth it reported for fiscal 2025.
Q4 fiscal 2025 total revenue was $682 million, up 13% year-over-year; subscription revenue was $670 million.
GAAP net income was $23 million, or $0.13 per diluted share, versus a GAAP net loss of $44 million a year earlier.
Non-GAAP diluted net income per share was $0.78, compared with $0.63 in the prior-year quarter.
For fiscal 2026, the company expects total revenue of $2.850 billion to $2.860 billion and non-GAAP diluted EPS of $3.15 to $3.20.
On February 27, 2025, AZZ Inc. signed a Fifth Amendment to its credit agreement with Citibank, N.A., lowering the interest rate margin and commitment and letter of credit fees on its $400 million senior secured revolving line of credit. The company's CFO said the repricing will significantly lower interest costs through the facility's maturity.
Revolving loan margins fall from 275-350 basis points to 175-275 basis points, subject to leverage ratio step-downs
Commitment fee falls from 25-37.5 basis points to 20-30 basis points; letter of credit fees fall from 425 basis points to 175-275 basis points
Amendment dated February 27, 2025; company announced completion in a press release dated March 3, 2025
TG Therapeutics reported fourth-quarter and full-year 2024 results, with full-year total revenue of $329.0 million and net income of $23.4 million, compared with $233.7 million and $12.7 million in 2023. The company set a 2025 target of approximately $540 million in total global revenue and said its $311.0 million in cash, cash equivalents and investment securities, combined with projected BRIUMVI revenue, should fund the business under its current operating plan.
Q4 2024 total revenue was $108.2 million, compared with $44.0 million in Q4 2023; Q4 2024 net income was $23.3 million, compared with a net loss of $14.4 million.
Full-year 2024 total revenue was $329.0 million, compared with $233.7 million in 2023; 2023 included recognition of a one-time $140.0 million Neuraxpharm upfront payment.
2025 target total global revenue is approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million.
Cash, cash equivalents and investment securities were $311.0 million as of December 31, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.